Synairgen provides update on progress during 2023

Proactive - Interviews for investors

Synairgen PLC chief executive Richard Marsden takes Proactive's Stephen Gunnion through the company's progress and future plans following the release of its full-year results. Marsden provided an overview of Synairgen's work over the past year, focusing on the development of an inhaled, broad-spectrum antiviral drug aimed at treating common respiratory viruses. He highlighted the exciting data generated from various clinical trials during the COVID-19 pandemic. Despite a decrease in hospitalisations due to current virus strains, the trials showed promising results in preventing severe outcomes in infected patients. Synairgen is now focusing on a Phase II trial for mechanically ventilated patients with severe viral lung infections. Marsden explained the rationale behind targeting this population, noting the high mortality rates and lack of antiviral therapeutic options for these patients. He also discussed the company's preparations for the trial, including lab work and collaborations with intensive care physicians. Marsden emphasised the strong commercial case for developing effective treatments in this area. Looking ahead, Synairgen is exploring funding options to support the upcoming trial, set to commence this winter. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #Synairgen #ClinicalTrials #RichardMarsden #AntiviralDrug #RespiratoryViruses #Phase2Trial #COVID19 #MedicalResearch #HealthcareInnovation #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews